A practical reference on Regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-31 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Somalia, officially the Federal Republic of Somalia, is the easternmost country in continental Africa. Stretching across the Horn of Africa, it borders Ethiopia to the west, Djibouti to the northwest, Kenya to the southwest, the Gulf of Aden to the north, and the Indian Ocean to the east. Somalia has the longest coastline on Africa's mainland. Somalia has an estimated population over 19 million, of which 2.7 million live in the capital and largest city, Mogadishu. As one of Africa's most ethnically homogeneous countries, around 85% of its residents are ethnic Somalis. The official and national language of the country is Somali, and Arabic is recognised as a second language. The overwhelming majority of the population are Sunni Muslims. In ancient history, Somalia was an important commercial centre. During the Middle Ages, several powerful Somali empires dominated the regional trade, including the Ajuran Sultanate, Adal Sultanate, and the Sultanate of the Geledi. In the late 19th century, the Somali sultanates were colonised by the Italian and British empires, who merged these tribal territories into two colonies: Italian Somaliland and British Somaliland. In 1960, the two territories united to form the independent Somali Republic under a civilian government. Siad Barre of the Supreme Revolutionary Council (SRC) seized power in 1969 and established the Somali Democratic Republic, launching a failed invasion of Ethiopia which triggered major instability in Somalia and brutally attempting to quash the Somaliland War of Independence in the north of the country.
=== Salvage pathways === Despite the presence of the de novo pathway, the salvage reactions are essential in humans; a lack of vitamin B3 in the diet causes the vitamin deficiency disease pellagra. This high requirement for NAD+ results from the constant consumption of the coenzyme in reactions such as posttranslational modifications, since the cycling of NAD+ between oxidized and reduced forms in redox reactions does not change the overall levels of the coenzyme. The major source of NAD+ in mammals is the salvage pathway which recycles the nicotinamide produced by enzymes utilizing NAD+. The first step, and the rate-limiting enzyme in the salvage pathway is nicotinamide phosphoribosyltransferase (NAMPT), which produces nicotinamide mononucleotide (NMN). NMN is the immediate precursor to NAD+ in the salvage pathway. Besides assembling NAD+ de novo from simple amino acid precursors, cells also salvage preformed compounds containing a pyridine base. The three vitamin precursors used in these salvage metabolic pathways are nicotinic acid (NA), nicotinamide (Nam) and nicotinamide riboside (NR). These compounds can be taken up from the diet and are termed vitamin B3 or niacin. However, these compounds are also produced within cells and by digestion of cellular NAD+. Some of the enzymes involved in these salvage pathways appear to be concentrated in the cell nucleus, which may compensate for the high level of reactions that consume NAD+ in this organelle.
=== Ammonia and glutamine synthesis === During exercise when the ATP reservoir is low (ADP>ATP), the purine nucleotide cycle produces ammonia (NH3) when it converts AMP into IMP. (With the exception of AMP deaminase deficiency, where ammonia is produced during exercise when adenosine, from AMP, is converted into inosine). During rest (ADP<ATP), ammonia is produced from the conversion of adenosine into inosine by adenosine deaminase.
Sources: en.wikipedia.org
== Actions == Neurons communicate with each other through synapses, specialized contact points where neurotransmitters transmit signals. When an action potential reaches the presynaptic terminal, voltage-gated calcium channels open, allowing calcium ions to enter the terminal. This calcium influx triggers the fusion of synaptic vesicles with the presynaptic membrane, leading to the release of neurotransmitters into the synaptic cleft. These neurotransmitters then bind to receptors on the postsynaptic membrane, influencing the receiving neuron in either an inhibitory or excitatory manner. If the overall excitatory influences outweigh the inhibitory influences, the receiving neuron may generate its own action potential, continuing the transmission of information to the next neuron in the network. This process allows for the flow of information and the formation of complex neural networks.
The 1982–83 Football League Trophy was the second edition of the Football League Group Cup, which had been renamed the Football League Trophy. It was won by Millwall, who beat Lincoln City 3–1 in the final at Sincil Bank. Next season the tournament would be reconstituted as the Associate Members' Cup which runs as the EFL Trophy today.
The Russian Partition (Polish: zabór rosyjski) constituted the former territories of the Polish–Lithuanian Commonwealth that were annexed by the Russian Empire in the course of late-18th-century Partitions of Poland. The Russian acquisition encompassed the largest share of the Polish–Lithuanian Commonwealth's population, living on 463,200 km2 (178,800 sq mi) of land constituting the eastern and central territory of the former Commonwealth. The three partitions, which took place in 1772, 1793 and 1795, resulted in the complete loss of Poland's and Lithuania's sovereignty, with their territories split between Russia, Prussia and Austria. The majority of Lithuania's former territory was annexed by the Russian Empire, except for Užnemunė (a geographical area on the left bank of the River Neman) which was annexed by Prussia. The Napoleonic Wars saw significant parts of Prussia's and Austria's partitions reconstituted as the Duchy of Warsaw (a French client state in a personal union under Saxony), most of which was then reconstituted as the Kingdom of Poland within the Russian Empire in 1815.
The class B metallo-β-lactamases (MBLs) are found largely in gram-negative bacteria and environmental bacteria. The subclasses of MBL enzymes are B1, B2, and B3. MBLs have diverse enzymatic functions and have the ability to hydrolyze β-lactam antibiotics. The class D β-lactamases (OXA), which hydrolyze oxacillin, provide a good example of the variety of mechanisms that can be used to transfer resistance. The blaOXA genes which encode OXA β-lactamases are found on both chromosomes and plasmids, and they have their natural reservoir in environmental bacteria and deep-sea microflora. Insertions in the vicinity of these genes have been shown to increase the strength of their promoters and increase resistance. Because of these characteristics, a wide geographic dissemination of OXA carbapenemase resistance in particular has occurred. The facilitated spread of carbapenem resistance appears to have multiple origins and repeated introduction into the UK of bacteria with the blaOXA-48 gene via horizontal transfer of similar plasmids to pOXA-48a.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.